1

Give simply more

What is PraxisPlatform?

PraxisPlatform is an ICT-supported* patient communication platform which is focused on:

• sending therapy-related information to patients to increase their adherence/compliance in medicinal therapy and medical device use

• enabling pharmacy care services to large patient populations

We have successfully commercialized a streamlined platform which brings more health to patients, more revenue to pharma and medical device companies and savings to payers.

* ICT – Information and communication technology

2

About the company

• PraxisPlatform has been developed by health economists and managed care experts in Central Europe, a challenging environment characterized by limited health care resources and low health consciousness of the population.

• We employ a staff of about 30 people in Budapest, specialized in the following areas:

• Clinical content development

• Sales & Marketing

• Customer service (incl. call center)

• IT development

3

PraxisPlatform has been through four years of quick expansion

4

After some years at the Hungarian sick fund, a small team of committed professionals starts to develop PraxisPlatform in June 2010

In December 2010, the first pilot project in patient adherence management starts in co-operation with the Hungarian subsidiary of Deutsche Telekom group and Sanofi-Aventis

By early 2012, PraxisPlatform is able to offer complex market research services and launches its real-life evidence generation module (non-interventional studies)

In December 2012, PraxisPlatform teams up with one of the leading Hungarian pharmacy chains to offer pharmacy care services and to manage its client loyalty programme

In May 2011, PraxisPlatform and Magyar Telekom sign a commercial deal and Magyar Telekom markets the product in HungarySince then projects are launched every month in patient adherence management.

In 2013, PraxisPlatform launches a disease registry module and offers a transplantation registry

In Summer 2013, the 100.000th patient is registered

4

PraxisPlatform in figures (1 Feb 2014)

25Companies60% of all potential partners

4.700Physicians30% of all active physicians, 1.500 active users*

112Pharmacies **

5Modules***

Went live

1 Oct 2010

112.000Patients

Geographies

Hungary 50Programmes

* Inactive physicians who have contracted with PraxisPlatform, can be reached by PraxisPlatform, but have not enrolled any patients to programmes yet. They are still learning system functions or waiting for the appropriate programme for their patients.** In co-operation with one of the largest Hungarian pharmacy chains*** Patient education and pharmacy care, market research, clinical trial, patient registry, screening

5

What services are currently offered by PraxisPlatform?6

* NIS: Phase IV non-interventional trials, PAES: Post-authorization efficacy studies , MES/PAS: Managed entry schemes / patient access schemes

Patient education

and pharmacy

care

Disease registries

Real-life evidence

generation(NIS, PAES, MES/PAS)*

Primary market

research

Patient screening

Data mining E-detailingPharmaco-vigilance Independent module

Additional services

Core module

Current situation of PraxisPlatform

PraxisPlatform has reached a dominant position in Hungary, a Central European EU member state of 10 million people where further growth opportunities are limited because of the size of the country

The value of Hungary is that it is often used as a test market by Big Pharma: if an idea works in Hungary, it is likely to work in several other markets

PraxisPlatform has an infrastructure to service more patients, physicians and doctors in more geographies

PraxisPlatform has the clinical, ICT and sales know-how which can be transferred to absolutely different regions

PraxisPlatform is an integrated platform which is difficult to copy: individually existing separate modules do not pose a threat to the business concept

PraxisPlatform has IRP protection for the EU

PraxisPlatform isinterested in TECHNOLOGY TRANSFER to major geographies with developed health care markets

PraxisPlatform isinterested in COMMERCIALIZATION AGREEMENTS to extend its services to other regions

1

2

7

PraxisPlatform – Technology transfer and commercialization deal opportunity

Ve r m a r k t u n g

( „ D i e n s t l e i s t u n g ” )Technology transfer

(„clone”)

PraxisPlatform has been developed with approx. 50.000 IT developer hours over 3 years

Based on our experience and knowhow, our team is able to develop and test a clone of our system in 3-4 months

In this model, our team builds, test and launches the clone and trains the buyer

We are not involved in further operations and all rights stay with the buyer for the relevant geography

In this model, we commit ourselves to operating PraxisPlatform with a business partner who wishes to introduce this service in a new geography

We co-develop the business model, we carry out the necessary modifications and we maintain active involvement in operations via our service center in Budapest

All rights stay with us, and we set up a revenue or profit sharing scheme with the commercial partner

Commercialization

(„service”)

8

ABOUT THE EDUCATIONAL PROGRAMMES

Starting point: Non-adherence, the most devastating illness of the modern world

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 190%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%100%

46%

38%

29%25%

22%19% 18%

Months after therapy initiation

% o

f p

ati

en

ts o

f th

era

py

Patients’ adherence to treatment is disconcertingly low throughout the developed world in practically all major

chronic diseases.

Large scale study (n=459.034), Hungary, statins

Source: Dankó – Frang – Molnár: Patients’ adherence to statin treatment. Corvinus University of Budapest, 2010, n= 459.034, based on National Health Insurance Fund financial database, 2007.01.01 – 2009.12.31

10

The key goal of PraxisPlatform is to help, educate and empower

Termék Kommunikációs eszköz és tartalom

Egyébszolgáltatások

Product Communicationtool and content

OtherServices

Motivated, health-conscious and satisfied patient, who is healthier

11

How educational programmes work…

12

They commission PraxisPlatform to (co-)develop therapy management, adherence management and pharmacy care programmes for their products and services.

PraxisPlatform usually works together with pharma and medical device companies but health insurers, patient advocacy groups and clinical organizations are also valued clients.

PHYSICIANS PHARMACISTS

HEALTH CARE COMPANIES

They enrol patients (customers) into the

programmes offered by PraxisPlatform.

They receive feedback about their patients’

health behaviour. They are remunerated

proportionally to their workload in a legal and

ethical way.

They enrol patients (customers) into the programmes offered by PraxisPlatform.They receive feedback about their patients’ health behaviour. They are remunerated proportionally to their workload in a legal and ethical way.

PATIENTS

Patients receive therapy-related information, general health information, pharmacy care information and eventually nursing and along an optimized timeline. Patients receive all services without payment.Patients can contact their physician and pharmacist via PraxisPlatform. Patients form patient communities.

12

Case study 1: supporting the launch of an original drug

• Combination product for the treatment of benign prostatic hypertrophy

• Active substance: dutasteride+tamsulosine

• Programme duration for each patient: 6 months

• Segmentation fee: 6.5 euro

• Target group: urologists (approx. 300 registered specialists)

• Goal: support to field activity upon product launch

13

Brief summary of the results

Persistence improvement is between 15 and 20 percent. Active group: patients who have received full education. Control group: patients who have not received full education.

14

Case study 2: Replacing sales activities for an off-patented original drug

• The programme was launched for patients who received lipid-lowering therapy because of their pathodologically high trigliceride level and unfavourable cholesterol level.

• Active substance: fenofibrate

• Programme duration: 6 months

• Segmentation fee: 3.5 euro

• Number of enrolled patients: 5045

• Medical target group is too wide to be covered by field force: more than 2000 doctors, incl. internal medicine specialists, GP’s and cardiologists

• Goal: subsitution of field force activity while maintaining the market position of the product

15

Brief summary of the results

We have data about patient persistence in fibrate lipid-lowering therapy in Hungary. The analysis is based on the data of the Hungarian National health Insurance Fund Administration..Source: Molnár M. P. – Pálosi M. (2012): Patient adherence (persistence) in fibrate lipid-lowering therapy, Medical Tribune, October 2012

The persistence curve for the active group is based on a random phone survey in which a representative sample of 100 enrolled patients (based on age, gender and residence) was interviewed about their medication-taking habits.

Persistence increased more than twofold. 75 per cent of patients were on newly initiated therapy. As a result, sales stabilised and showed an increase of 2 per cent despite the cancellation of all field force activities.

16

Case study 3: replacing sales acitivies for an off-patented original drug

• The programme was designed for patients who suffer from osteoporosis. It helps them possess a deeper knowledge of the disease and follow medicinal therapy more properly.

• Active subtance: alendronic acid

• Programme duration for patients: 7.5 months

• Segmentation fee: 6.5 euro

• Medical target group: wide scope of physicians (GP’s, orthopedic surgeons, traumatologists, rheumatologists

• Goal: substitution of field force activity, protection of market positions

17

Brief summary of the results

Persistence increased almost twofold. 78 per cent of patients were on newly initiated therapy. As a result, the downward trend of sales was halted and stabilized.

We have data about patient persistence in oral bisphosphonate therapy in Hungary. The analysis is based on the data of the Hungarian National health Insurance Fund Administration..

The persistence curve for the active group is based on a random phone survey in which a representative sample of 100 enrolled patients (based on age, gender and residence) was interviewed about their medication-taking habits.

18

Case study 4: supporting an oncological original drug

• The programme was designed for patients suffering from HER2+ metastatic breast cancer.

• Active substance: Lapatinib

• Porgramme duration for patients: 6 months

• Segmentation fee: none

• Goal: To enable physicians to help their breast cancer patients better cope with their condition and follow medicinal therapy more properly, with special regard to eventual side effects

• Medical target group: clinical oncologists

• The programme offered comprehensive medical care including personal visits at the patient’s home.

19

Brief summary of the results

Although the programme was not expected to prolong therapy duration with end-stage patients, such improvement was in fact registered. This is attributable to the appropriate management of side effect during therapy.

20

Programmes and therapeutic areas

Range of therapeutic areas covered by PraxisPlatform:

• Hypertension • Incontinence (diaper) • Asthma • Prostate hypertrophy • Anticoagulant therapy • Parinson’s • COPD • Breast cancer • Arthrosis • Depression • Hyperlipidaemia • HPV treatment • Heart failure/angina pectoris • Stroke • Diabetes mellitus (measurement)

• Osteoporosis • Gastrooesophagialis reflux • Chronic myeloid leukaemia • Allergy • Erectile dysfunction • Cachexia-anorexia – oncology • Diabetes mellitus• Cardiovascular disease • Metabolic syndrome • Health promotion/prevention • Pregnancy • Probiotics • Inflammatory Bowel Disease

21

Parts of educational programmesBasic programme dataDeadlines, goals and therapy, sponsoring health care company, financing, description, programme messages

Information leaflet for physiciansabout therapy & drug, how to enrol patients in a programme

Information leaflet for patientsabout therapy & drug; suggestions for the therapy

QuizThe quiz is dedicated to patients in a specific programme and consists of questions about the therapy, providing a possibility for the patient to test his or her knowledge about the therapy.

DiaryPatients in a programme can fill in a daily or weekly ‚diary’ consisting of questions about the specific therapy and/or the patient’s medical condition. The patient’s physician can read the diary entries.

QuestionnaireAt the end of a programme, patients can fill in a satisfaction survey serving for the evaluation of the programme.

StatisticsStatistics about the patients in the programme

Patient callsIn certain programmes, the involved physician has to carry out consultations with the patient via phone call.

Programme messagesPatients can read (or listen to) all programme messages (email, text, recorded voice message) already sent by PraxisPlatform. For physicians all programme messages are available.

22

ABOUT MARKET RESEARCH

Market research

Physicians can be enrolled into programme-specific or programme-independent market research. They are compensated for filling in the market research questionnaire.

24

ABOUT CLINICAL TRIALS

Clinical trials

Within PraxisPlatform’s real-life evidence generation module, physicians can be invited to program-specific or program-independent, prospective, non-interventional clinical studies. The PraxisPlatform system is able to manage the whole process of a clinical trial from enrolling a patient into the trial through filling out the visit data up to handling the financial processes (both physicians and supporting health care company).

26

ABOUT DISEASE REGISTRIES

Disease registry

PraxisPlatform offers to specific therapeutic areas disease registries with the following main functions:

• invited physicians can enrol their patients into a registry

• in the registry module, they can fill in visit questionnaires

• physicians are notified about recommended patient visits via email

• patients can also be notified about recommended visits via email, text message or voice message

• the module can handle the financial processes related to the physician's activity

28

Transplant registry

The transplant registry is a specific patient registry enabling physicians working at a transplant institute

1. to enrol their patients as recipients in the transplant registry

2. to enter transplant-specific donor data into the donor database

3. to fill in all relevant medical data of transplant operations.

29

BENEFITS OFFERED BY PRAXISPLATFORM TO ITS CLIENTS

How do patients benefit from PraxisPlatformTM?

• Free access to all patient features of PraxisPlatformTM

• Guidance to take medicines and use medical devices properly

• Guidance on lifestyle, health behavior and adherence to therapy

• Easy-to-access web content about disease and treatment

• Additional, flexible contact with treating specialist

• Comprehensive call center support (active and passive)

• Web-based patient communities

• In certain programmes: totally interactive features

• Patient retention is 98% in our running programmes

31

What are physicians’ and pharmacists’ benefits?

• Free access to all core modules

• Easy and tailor-made communication with patients, saving time and reducing workload

• Possibility to access large populations at no cost*

• Access to a comprehensive range of ready-to-send programmes uploaded by pharmaceutical and medical device companies

• Telemedicine and virtual chronic care features

• Possibility to participate in clinical research and market surveys

• Remuneration proportional to time spent on data management

• Feedback on patients’ adherence and drug consumption

32

Benefits offered by PraxisPlatform to health care companies

Clinical benefits Commercial benefits

• Stronger adherence to treatment, better utilization of proprietary health technologies

• Higher real-life therapeutic effectiveness

• Lower risk of switches and therapy discontinuation

• Possibility to participate in patient education

• Increasing revenues

• Higher adherence / persistence

• Higher brand awareness

• Higher perceived drug value

• Balanced marketing channel mix

• Favorable programme cost structure

• Low costs of reaching patients

• Targeted, flexible campaigns

33

MAJOR REFERENCES OF PRAXISPLATFORM

Major references of PraxisPlatform

35

CONTACT: info@praxisplatform.hu